New immune cell attack tested for tough blood cancers
Disease control
Not yet recruiting
This early-stage study is testing the safety of a new combination treatment for people with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment adds an experimental therapy—'natural killer' (NK) immune cells from a donor—…
Phase: PHASE1 • Sponsor: Paolo Caimi, MD • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC